176 related articles for article (PubMed ID: 19422096)
1. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans. Part A: use of FDA post-market reports to create a database of hepatobiliary and urinary tract toxicities.
Ursem CJ; Kruhlak NL; Contrera JF; MacLaughlin PM; Benz RD; Matthews EJ
Regul Toxicol Pharmacol; 2009 Jun; 54(1):1-22. PubMed ID: 19422096
[TBL] [Abstract][Full Text] [Related]
2. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part B. Use of (Q)SAR systems for early detection of drug-induced hepatobiliary and urinary tract toxicities.
Matthews EJ; Ursem CJ; Kruhlak NL; Benz RD; Sabaté DA; Yang C; Klopman G; Contrera JF
Regul Toxicol Pharmacol; 2009 Jun; 54(1):23-42. PubMed ID: 19422098
[TBL] [Abstract][Full Text] [Related]
3. Identification of structure-activity relationships for adverse effects of pharmaceuticals in humans: Part C: use of QSAR and an expert system for the estimation of the mechanism of action of drug-induced hepatobiliary and urinary tract toxicities.
Matthews EJ; Kruhlak NL; Benz RD; Aragonés Sabaté D; Marchant CA; Contrera JF
Regul Toxicol Pharmacol; 2009 Jun; 54(1):43-65. PubMed ID: 19422100
[TBL] [Abstract][Full Text] [Related]
4. Prediction of drug-related cardiac adverse effects in humans--A: creation of a database of effects and identification of factors affecting their occurrence.
Matthews EJ; Frid AA
Regul Toxicol Pharmacol; 2010 Apr; 56(3):247-75. PubMed ID: 19932726
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Matthews EJ; Kruhlak NL; Weaver JL; Benz RD; Contrera JF
Curr Drug Discov Technol; 2004 Dec; 1(4):243-54. PubMed ID: 16472241
[TBL] [Abstract][Full Text] [Related]
6. Prediction of drug-related cardiac adverse effects in humans--B: use of QSAR programs for early detection of drug-induced cardiac toxicities.
Frid AA; Matthews EJ
Regul Toxicol Pharmacol; 2010 Apr; 56(3):276-89. PubMed ID: 19941924
[TBL] [Abstract][Full Text] [Related]
7. Construction and analysis of a human hepatotoxicity database suitable for QSAR modeling using post-market safety data.
Zhu X; Kruhlak NL
Toxicology; 2014 Jul; 321():62-72. PubMed ID: 24721472
[TBL] [Abstract][Full Text] [Related]
8. Comparing drug safety of hepatitis C therapies using post-market data.
Huang J; Zhang X; Tong J; Du J; Duan R; Yang L; Moore JH; Tao C; Chen Y
BMC Med Inform Decis Mak; 2019 Aug; 19(Suppl 4):147. PubMed ID: 31391106
[TBL] [Abstract][Full Text] [Related]
9. Likelihood ratio test-based method for signal detection in drug classes using FDA's AERS database.
Huang L; Zalkikar J; Tiwari RC
J Biopharm Stat; 2013; 23(1):178-200. PubMed ID: 23331230
[TBL] [Abstract][Full Text] [Related]
10. Profiling cumulative proportional reporting ratios of drug-induced liver injury in the FDA Adverse Event Reporting System (FAERS) database.
Brinker AD; Lyndly J; Tonning J; Moeny D; Levine JG; Avigan MI
Drug Saf; 2013 Dec; 36(12):1169-78. PubMed ID: 24178291
[TBL] [Abstract][Full Text] [Related]
11. Adverse drug and device reactions in the oral cavity: surveillance and reporting.
Zavras AI; Rosenberg GE; Danielson JD; Cartsos VM
J Am Dent Assoc; 2013 Sep; 144(9):1014-21. PubMed ID: 23989840
[TBL] [Abstract][Full Text] [Related]
12. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
13. Novel adverse events of bevacizumab in the US FDA adverse event reporting system database: a disproportionality analysis.
Shamloo BK; Chhabra P; Freedman AN; Potosky A; Malin J; Weiss Smith S
Drug Saf; 2012 Jun; 35(6):507-18. PubMed ID: 22612854
[TBL] [Abstract][Full Text] [Related]
14. Topical bovine thrombin: a 21-year review of topical bovine thrombin spontaneous case safety reports submitted to FDA's Adverse Event Reporting System.
Clark JA; Humphries JE; Crean S; Reynolds MW
Pharmacoepidemiol Drug Saf; 2010 Feb; 19(2):107-14. PubMed ID: 20014051
[TBL] [Abstract][Full Text] [Related]
15. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
[TBL] [Abstract][Full Text] [Related]
16. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system.
Raschi E; Poluzzi E; Koci A; Salvo F; Pariente A; Biselli M; Moretti U; Moore N; De Ponti F
Br J Clin Pharmacol; 2015 Aug; 80(2):285-93. PubMed ID: 25689417
[TBL] [Abstract][Full Text] [Related]
17. Reported Adverse Events with Painkillers: Data Mining of the US Food and Drug Administration Adverse Events Reporting System.
Min J; Osborne V; Kowalski A; Prosperi M
Drug Saf; 2018 Mar; 41(3):313-320. PubMed ID: 29098610
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
[TBL] [Abstract][Full Text] [Related]
19. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
Aagaard L; Hallgreen CE; Hansen EH
Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
[TBL] [Abstract][Full Text] [Related]
20. Prospective data mining of six products in the US FDA Adverse Event Reporting System: disposition of events identified and impact on product safety profiles.
Bailey S; Singh A; Azadian R; Huber P; Blum M
Drug Saf; 2010 Feb; 33(2):139-46. PubMed ID: 20082540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]